Netherlands· NL-3fcfcaaf0e25
Pombiliti 105mg, poeder voor concentraat voor oplossing voor injectie/infusie
A cipaglucosidase alfa product containing cipaglucosidase alfa, registered in Netherlands by Amicus Therapeutics Europe Limited. The same ATC class is registered in 13 of our 19 countries.
Checked against CBG-MEB (Netherlands) on
Informational only — not a medical device.
Where it is registered
Cipaglucosidase alfa is registered in 13 of 19 countries.
Countries holding a registration under ATC A16AB23 (cipaglucosidase alfa), each read from that country’s own register.
- This record: Netherlands, from CBG-MEB (Netherlands)
- 9 of them publish a price we can compare per daily dose
Cipaglucosidase alfa · ATC A16AB23
13 / 19 countries
- Belgiumprice
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Icelandprice
- Ireland
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of cipaglucosidase alfa costs, country by country.
Normalised to the WHO defined daily dose (0.1 g), so markets compare like for like.
- 1 market with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Cipaglucosidase alfa · price per daily dose (0.1 g)
USD · FX 28 Sept 2026
- CH Switzerland$1264.16
The record
At a glance
CBG-MEB (Netherlands)- Active substance
- CIPAGLUCOSIDASE ALFA
- Manufacturer
- Amicus Therapeutics Europe Limited
- Country
- Netherlands (NL)
- ATC code
- A16AB23
- ATC class
- Cipaglucosidase alfa
- Defined daily dose
- 0.1 g, P
- Reimbursed
- Not published by this register
- Source register
- CBG-MEB (Netherlands)
- Last checked
- September 29, 2026
Packs & prices · 1
- cbg_meb_idEU/1/22/1714
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Cipaglucosidase alfa in 14 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- FrancePOMBILITI 105 mg, poudre pour solution à diluer pour perfusionAMICUS THERAPEUTICS EUROPE (IRLANDE)
- SwitzerlandPombiliti 105 mg, Pulver für ein Konzentrat zur Herstellung einer InfusionslösungAmicus Therapeutics Switzerland GmbH
- CzechiaPOMBILITIAmicus Therapeutics Europe Limited, Dublin
- United StatesPOMBILITIAMICUS THERAPEUTICS US, LLC
- United KingdomPombiliti 105mg powder for concentrate for solution for infusion vialsAmicus Therapeutics UK Operations Ltd
- BelgiumPombiliti 105 mgAmicus Therapeutics Europe
- IcelandPombilitiAmicus Therapeutics Europe Limited*
- Japanシパグルコシダーゼ アルファ(遺伝子組換え)アミカス・セラピューティクス
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Pombiliti
- Liechtenstein · Pombiliti
- Norway · Pombiliti
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of CBG-MEB (Netherlands). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/591cf064-20e8-4511-b43a-8f960f50d3af GET /v1/drugs/591cf064-20e8-4511-b43a-8f960f50d3af?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Poeder voor concentraat voor oplossing voor infusie",
"route": "Intraveneus gebruik",
"soort": null,
"source": "cbg_meb",
"smpc_url": "https://www.ema.europa.eu/en/documents/product-information/pombiliti-epar-product-information_nl.pdf",
"strength": null,
"atc_label": "Cipaglucosidase Alfa",
"detail_url": "https://www.geneesmiddeleninformatiebank.nl/nl/cp129217",
"excipients": [
"CITROENZUUR 1-WATER (E 330)",
"MANNITOL (D-) (E 421)",
"POLYSORBAAT 80 (E 433)",
"STIKSTOF (HEAD SPACE) (E 941)",
"TRINATRIUMCITRAAT 2-WATER (E 331)"
],
"substances": [
"CIPAGLUCOSIDASE ALFA"
],
"leaflet_url": null,
"authorised_at": "2023/03/20",
"procedure_number": "EMEA/H/C/005703",
"dispensing_status": "Uitsluitend recept",
"registration_number": "EU/1/22/1714",
"additional_monitoring": "Y"
}See everything about cipaglucosidase alfa.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.